Aratana Therapeutics (PETX) Tops Q3 EPS by 3c

Aratana Therapeutics (NASDAQ: PETX) reported Q3 EPS of ($0.36), $0.03 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $229 thousand versus the consensus estimate of $250 thousand.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Reading (RDI) Tops Q2 EPS by 4c